Arndt Vogel· @ArndtVogel · X·· 2 天前评分90
正文 · 原文
RASolute 302 ph3 study: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated mPDAC
#ESMO26 #ESMOAmbassadors
👉 mOS: 13.2 vs 6.7 mo
👉ORR improved in all RAS mutations
👉PFS & OS: small subgroups, favourable for all
🧐great data, consistent benefits for all pts
@myESMO @ASCO
1123 浏览 · 28 赞 · 19 转发 · 0 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org来源：Arndt Vogel · x.com